Lorraine Kreider
Internal Medicine · Bedford, TXNPI 1194700344
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 240 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 13.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,116 and has fallen 99.0% since, to $22 in 2023.
Across 240 payments — averaging $12.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$409
- Novo Nordisk$364
- AstraZeneca$301
- Pfizer$293
- Amarin Pharma, Inc.$204
- Boehringer Ingelheim$185
- plus $1K from 29 others
What the payments were for
- Food & beverage$2,93399%
- Education$211%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 30 | $409 |
| Novo Nordisk | 43 | $364 |
| AstraZeneca | 23 | $301 |
| Pfizer | 32 | $293 |
| Amarin Pharma, Inc. | 11 | $204 |
| Boehringer Ingelheim | 12 | $185 |
| AbbVie(2 entities) | 11 | $172 |
| Takeda Pharmaceuticals U.S.A., Inc. | 18 | $165 |
| Amgen | 10 | $145 |
| Abbott | 7 | $113 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $81 |
| Astellas Pharma US Inc | 3 | $53 |
| Johnson & Johnson(2 entities) | 3 | $40 |
| Novartis | 3 | $38 |
| Kowa Pharmaceuticals America, Inc. | 2 | $29 |
| Genentech USA, Inc. | 2 | $29 |
| Lilly USA, LLC | 2 | $27 |
| Nalpropion Pharmaceuticals LLC | 2 | $25 |
| Bausch Health US, LLC | 2 | $25 |
| Merck | 2 | $24 |
| Sanofi Pasteur Inc. | 2 | $24 |
| Sanofi-aventis U.S. LLC | 2 | $23 |
| Biohaven Pharmaceuticals, Inc. | 1 | $20 |
| Optinose US, Inc. | 1 | $19 |
| Mission Pharmacal Company | 1 | $19 |
| Mylan Specialty L.p. | 1 | $17 |
| Regeneron Healthcare Solutions, Inc. | 1 | $16 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
| Neuronetics, Inc. | 1 | $12 |
| Avanir Pharmaceuticals, Inc. | 1 | $12 |
| Eisai Inc. | 1 | $12 |
| Antares Pharma, Inc. | 1 | $11 |
| Currax Pharmaceuticals LLC | 1 | $11 |
| Circassia Inc. | 1 | $11 |
How this compares
$2,954 in reported general payments places this provider in the 80th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Bedford
- Spencer BerthelsenSugar Land$891K
- Hameed AliTemple$773K
- Marc TribbleDallas$693K
- Gary SinclairDallas$599K
- Mohammed Al-NajjarEl Paso$586K
- Han SchmidlyDallas$465K
- Hussein TawbiHouston$365K
- Hans LeeHouston$327K
- Tapan KadiaHouston$311K
- Nitin JainHouston$281K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.